Paul Chaplin, president and CEO of Bavarian Nordic
Small RSV contender eyes 'first-to-market' opportunity with $225M Asia deal
As Bavarian Nordic — one of the smaller players in the RSV vaccine race — gears up for a Phase III trial of its candidate, it’s lined up a partner to handle things on the Asian side.
Shanghai’s Nuance Pharma is dropping $12.5 million upfront to license regional rights to MVA-BN RSV, a poxvirus-based vaccine that contains five RSV antigens to stir up immunity against the respiratory syncytial virus. Milestones add up to $212.5 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
